Compare PRE & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRE | RCEL |
|---|---|---|
| Founded | 2014 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.3M | 114.3M |
| IPO Year | N/A | N/A |
| Metric | PRE | RCEL |
|---|---|---|
| Price | $16.56 | $3.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $32.00 | $11.75 |
| AVG Volume (30 Days) | 137.5K | ★ 196.2K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,079,000.00 | $72,401,000.00 |
| Revenue This Year | $219.28 | $13.12 |
| Revenue Next Year | $124.38 | $27.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 201.54 | 20.59 |
| 52 Week Low | $3.10 | $3.33 |
| 52 Week High | $17.99 | $14.16 |
| Indicator | PRE | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 63.85 | 33.64 |
| Support Level | $14.02 | $3.33 |
| Resistance Level | $15.70 | $3.58 |
| Average True Range (ATR) | 1.18 | 0.18 |
| MACD | 0.18 | 0.00 |
| Stochastic Oscillator | 94.44 | 12.50 |
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.